HEOR Staff Writer

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Ph...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
FDA Guidance on Overall Survival Assessment in Oncology Trials